Anika Therapeutics, Inc.
ANIK· Nasdaq
ANIKAnika Therapeutics, Inc.
Released Apr 29, 2026, before the open
10-Q filed Apr 30, 2026, 30 days after period end · 0001171843-26-002852
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $29.61M | $26.17M | $29.02M | $37.92M |
| Net Income | -$5.06M | -$4.87M | -$4.51M | -$10.35M |
| EPS Diluted |
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
| -$0.37 |
| -$0.34 |
| -$0.31 |
| -$0.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
